DOCSLIB.ORG

13305 Program E.Indd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
13305 Program E.Indd 4th DIA Cardiac Safety Workshop in Japan July 11-12, 2013 Ivy Hall - Tokyo OVERVIEW PROGRAM CHAIR Koki Nakamura, MD, PhD Drug eff ect on the cardiac repolarization and the potential for drug Takeda Pharmaceutical Company Limited induced arrhythmia has long been recognized as a public health issue. In November 2010 the Japanese Pharmaceuticals and Medical Devices PROGRAM VICE-CHAIR Agency (PMDA) ratifi ed the ICH-E14 guidance in Japan. In compliance with the ICH-E14 requirements, a Thorough QT (TQT) Study, or an Boaz Mendzelevski, MD alternative QT assessment program, must be provided in support BioClinica, Inc., United Kingdom of nearly all New Drug Applications (NDA) in Japan. The science of designing, conducting and analysing TQT studies and the experience of PROGRAM COMMITTEE running these programs in Japan are rapidly evolving. Hiroyuki Fukase, MD, PhD CPC Clinical Trial Hospital In addition, the recognition that cardiotoxicity of new drugs may Medipolis Medical Research Institute involve other cardiovascular (CV) targets and mechanisms, have led to Zhe Jin, MD, PhD clinical and regulatory focus on specifi c drug classes and therapeutic TAIHO Pharmaceutical Co., Ltd. areas associated with CV toxicity, including oncology, rheumatology, endocrinology and metabolism, etc. New regulations have been Yuji Kumagai, MD, PhD introduced in some major regulatory jurisdictions to assess and Kitasato University East Hospital mitigate such adverse cardiac drug eff ects. Kaori Shinagawa, MD, PhD Pharmaceuticals and Medical Devices Agency The 4th Cardiac Safety Workshop in Japan will provide an interactive (PMDA) platform to discuss the above and similar topics. Atsushi Sugiyama, MD, PhD Toho University PROGRAM ADVISOR Yoshiaki Uyama, PhD Pharmaceuticals and Medical Devices Agency (PMDA) Simultaneous Translation Available DIA Worldwide Headquarters 800 Enterprise Road, Suite 200 Horsham, PA 19044, USA Tabletop Exhibit Opportunity For information, contact DIA Japan Regional Offi ces Nisso 22 Bldg. 7F, 1-11-10 Azabudai, Basel, Switzerland | Beijing, China | Mumbai, India Tokyo, Japan | Washington, DC, USA Minato-ku, Tokyo 106-0041 Japan Tel: 81-3-5575-2130 | Fax: 81-3-3583-1200 email: [email protected] DAY 1 | THURSDAY, JULY 11, 2013 2 8:30-9:00 REGISTRATION MYRTOS (2F) 11:00-11:20 The Implementation Status of CV Safety Assessment 9:00-9:10 OPENING REMARKS MYRTOS (2F) Based on E14 Guideline in Japan Koki Nakamura, MD, PhD Kiyoshi Nobori Senior Director, Global Medical Aff airs-Japan, Takeda Development Reviewer, Offi ce of New Drug II, Pharmaceuticals and Medical Center Japan, Pharmaceutical Development Division, Takeda Devices Agency (PMDA) Pharmaceutical Company Limited 11:20-12:20 9:10-9:40 SESSION 1 - KEYNOTE PRESENTATION Panel Discussion SESSION CHAIR All speakers from this session Koki Nakamura, MD, PhD Senior Director, Global Medical Aff airs-Japan, Takeda Development 12:20-13:30 LUNCH BREAK SAFFRON (B2F) Center Japan, Pharmaceutical Development Division, Takeda Free Lunch Available Pharmaceutical Company Limited For Better Cardiac Safety Assessment 13:30-14:30 SESSION 3 MYRTOS (2F) Yuji Kumagai, MD, PhD Abstract Session Professor and Director, Clinical Trial Center SESSION CO-CHAIRS Kitasato University East Hospital Yuji Kumagai, MD, PhD Professor and Director, Clinical Trial Center 9:40-12:20 SESSION 2 MYRTOS (2F) Kitasato University East Hospital Global Regulatory Update Boaz Mendzelevski, MD Vice President of Cardiology, BioClinica, Inc., United Kingdom SESSION CO-CHAIRS Kaori Shinagawa, MD, PhD 13:30-13:45 Senior Scientist for Clinical Medicine, Pharmaceuticals and Medical Devices Agency (PMDA) Should the PR Interval be Corrected for Heart Rate Similarly to the QT Interval? Colette Strnadova, PhD Senior Scientifi c Advisor, Therapeutic Products Directorate, Health Boaz Mendzelevski, MD Canada Vice President of Cardiology, BioClinica, Inc., United Kingdom 9:40-10:00 13:45-14:00 Alternative ECG Assessment Strategies for Drugs that Drug Interaction Studies with Ketoconazole may Provide are Challenging to Assess by Conventional ICH E14 Type an Opportunity to Replace the TQT Study for 3A4 Approaches Substrates Colette Strnadova, PhD Börje Darpö, MD, PhD Senior Scientifi c Advisor, Health Canada Associate Professor of Cardiology, Pharmaceutical Consultant, Karolinska Institute, Sweden 10:00-10:20 14:00-14:15 CV Safety Assessment of Oncology Compounds: A Regulatory Update How can Processes in a Core ECG Laboratory Infl uence Assessment of Cardiac Repolarization in Thorough QT Krishna Prasad, MB, BS, MD, FRCP Clinical Assessor/Consultant Cardiologist Studies? Medicines and Healthcare products Regulatory Agency (MHRA), Snehal N. Kothari, MC, FACC United Kingdom Senior Medical Director Quintiles Cardiac Safety Services, India 10:20-10:40 14:15-14:30 FDA Recent Initiatives for Improving CV Safety Assessment Eff ect of a Meal on the QTC Interval is Used to Demonstrate ECG Assay Sensitivity in a Standard Japanese Karen A. Hicks, MD (pre-recorded presentation) Medical Offi cer, Division of Cardiovascular and Renal Products, PK Bridging Study Food and Drug Administration, USA Jöerg Täubel, MD, FFPM Chief Executive Offi cer Richmond Pharmacology Ltd., United Kingdom 10:40-11:00 The Future of the Thorough QT Study: The CSRC’s Perspective Börje Darpö, MD, PhD Associate Professor of Cardiology, Pharmaceutical Consultant, Karolinska Institute, Sweden DAY 1 | THURSDAY, JULY 11, 2013 3 14:30-17:30 SESSION 4 MYTROS (2F) 16:15-17:15 Experience in Pharmaceutical Companies Panel Discussion: SESSION CO-CHAIRS • How to Decide the Supra-therapeutic Dose: Timing Koki Nakamura, MD, PhD Versus Information of Special Population? Senior Director, Global Medical Aff airs-Japan, Takeda Development • Can we Replace TQT with Intensive Ph1? Center Japan, Pharmaceutical Development Division, Takeda Pharma- • How to Evaluate the Comprehensive CV Risks Including ceutical Company Limited BP and HR? Kaori Shinagawa, MD, PhD All speakers from this session and Senior Scientist for Clinical Medicine, Pharmaceuticals and Medical Kinue Nishioka, PhD Devices Agency (PMDA) Principal Reviewer, Offi ce of New Drug I, Pharmaceuticals and Medical Devices Agency (PMDA) 14:30-14:45 Hiroyuki Fukase, MD, PhD A TQT Study Case Where a Diff erent Method of Analysis Director, CPC Clinical Trial Hospital, Medipolice Medical Research was Requested Institute Masako Nakano, MD, PhD Yuji Kumagai, MD, PhD Clinical Pharmacology Medical, Eli Lilly Japan K.K. Professor and Director, Clinical Trial Center, Kitasato University East Hospital 14:45-15:00 Boaz Mendzelevski, MD Vice President of Cardiology, BioClinica, Inc., United Kingdom How to Determine the Supra-Therapeutic Dose in the QT/ Atsushi Sugiyama, MD, PhD QTc Study? Professor, Department of Pharmacology, School of Medicine, Shingo Tanaka Faculty of Medicine, Toho University Clinical Pharmacology, Takeda Pharmaceutical Company Limited 17:30-19:00 NETWORKING RECEPTION SAFFRON(B2F) 15:00-15:15 ECG Evaluation: Machine-reading Versus Manual Reading Koki Nakamura, MD, PhD Senior Director, Global Medical Aff airs-Japan, Takeda Development Center Japan, Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited 15:15-15:35 An Integrated ECG Monitoring Model with Uniform Standards Across Drug Development: Introducing the Novartis Clinical Safety Standard Guidelines Network with Professional Colleagues Pierre Jordaan, MD Anywhere Anytime! Cardiovascular Safety Expert, Drug Safety and Epidemiology, Novartis Pharma AG, Switzerland 15:35-16:05 COFFEE BREAK SAFFRON (B2F) DIA ConneX You 16:05-16:10 DIA’s members-only social networking- A Case of Being Exempted from Conducting a TQT Study, style website is a vital resource for profes- with Conditions, For a Compound Used Worldwide for sionals like you looking to connect with others Many Years in your field and improve your job performance. Yoshitaka Isaka, PhD Japan Senior Research Scientist, Clinical Pharmacology Medical, Thousands of your colleagues Eli Lilly Japan K.K. will be part of DIA ConneX, so don’t get left behind. 16:10-16:15 A Phase 1, Open-label Study to Evaluate the Cardiac Safety How Can DIA ConneX Help You? of a Cytotoxic Cancer Drug X in Patient with Advanced đƮ!0ƫ*/3!./ƫ0+ƫ+*ġ0$!ġ&+ƫ Solid Tumors questions Zhe Jin, MD, PhD đƮƫ!//ƫ/$.! ƫ.!/+1.!/ƫ/1$ƫ/ƫ Pharmacovigilance Department white papers and articles Taiho Pharmaceutical Co., Ltd. đƮƫ!03+.'ƫ3%0$ƫ0$+1/* /ƫ+"ƫ5+1.ƫ colleagues worldwide Get connected at www.diahome.org/DIAconnex. DAY 2 | FRIDAY, JULY 12, 2013 4 8:20-8:40 REGISTRATION MYRTOS (2F) 11:00-13:00 SESSION 6 MYRTOS (2F) Blood Pressure as a CV Safety Endpoint 8:40-10:30 SESSION 5 MYRTOS (2F) SESSION CO-CHAIRS Translational Medicine Hiroyuki Fukase, MD, PhD Director, CPC Clinical Trial Hospital SESSION CO-CHAIRS Medipolice Medical Research Institute Hiroyuki Fukase, MD, PhD Boaz Mendzelevski, MD Director, CPC Clinical Trial Hospital, Medipolice Medical Research Vice President of Cardiology, BioClinica, Inc., United Kingdom Institute Atsushi Sugiyama, MD, PhD Professor, Department of Pharmacology, School of Medicine, Faculty 11:00-11:20 of Medicine, Toho University Drug-induced Blood Pressure Changes: Mechanism and Clinical Relevance 8:40-9:00 Shinchiro Ueda, MB, ChB, PhD Professor, Department of Clinical Pharmacology & Therapeutics, Integrated Cardiac Safety: Preclinical and Early Clinical Graduate School of Medicine, University of the Ryukyus Data Hiroyuki Fukase, MD, PhD Director, CPC Clinical Trial Hospital, Medipolice Medical Research
Load more

Recommended publications
  • Toho Co., Ltd. Agenda
    License Sales Sheet October 2018 TOHO CO., LTD. AGENDA 1. About GODZILLA 2. Key Factors 3. Plan & Schedule 4. Merchandising Portfolio Appendix: TOHO at Glance 1. About GODZILLA About GODZILLA | What is GODZILLA? “Godzilla” began as a Jurassic creature evolving from sea reptile to terrestrial beast, awakened by mankind’s thermonuclear tests in the inaugural film. Over time, the franchise itself has evolved, as Godzilla and other creatures appearing in Godzilla films have become a metaphor for social commentary in the real world. The characters are no longer mere entertainment icons but embody emotions and social problems of the times. 2018 © TOHO CO., LTD. All rights reserved/ Confidential & Proprietary 4 About GODZILLA | Filmography Reigning the Kaiju realm for over half a century and prevailing strong --- With its inception in 1954, the GODZILLA movie franchise has brought more than 30 live-action feature films to the world and continues to inspire filmmakers and creators alike. Ishiro Honda’s “GODZILLA”81954), a classic monster movie that is widely regarded as a masterpiece in film, launched a character franchise that expanded over 50 years with 29 titles in total. Warner Bros. and Legendary in 2014 had reintroduced the GODZILLA character to global audience. It contributed to add millennials to GODZILLA fan base as well as regained attention from generations who were familiar with original series. In 2017, the character has made a transition into new media- animated feature. TOHO is producing an animated trilogy to be streamed in over 190 countries on NETFLIX. 2018 © TOHO CO., LTD. All rights reserved/ Confidential & Proprietary 5 Our 360° Business Film Store TV VR/AR Cable Promotion Bluray G DVD Product Exhibition Publishing Event Music 2018 © TOHO CO., LTD.
    [Show full text]
  • Hydrogen and Fuel Cells in Japan
    HYDROGEN AND FUEL CELLS IN JAPAN JONATHAN ARIAS Tokyo, October 2019 EU-Japan Centre for Industrial Cooperation ABOUT THE AUTHOR Jonathan Arias is a Mining Engineer (Energy and Combustibles) with an Executive Master in Renewable Energies and a Master in Occupational Health and Safety Management. He has fourteen years of international work experience in the energy field, with several publications, and more than a year working in Japan as an energy consultant. He is passionate about renewable energies, energy transition technologies, electric and fuel cell vehicles, and sustainability. He also published a report about “Solar Energy, Energy Storage and Virtual Power Plants in Japan” that can be considered the first part of this document and is available in https://lnkd.in/ff8Fc3S. He can be reached on LinkedIn and at [email protected]. ABOUT THE EU-JAPAN CENTRE FOR INDUSTRIAL COOPERATION The EU-Japan Centre for Industrial Cooperation (http://www.eu-japan.eu/) is a unique venture between the European Commission and the Japanese Government. It is a non-profit organisation established as an affiliate of the Institute of International Studies and Training (https://www.iist.or.jp/en/). It aims at promoting all forms of industrial, trade and investment cooperation between the EU and Japan and at improving EU and Japanese companies’ competitiveness and cooperation by facilitating exchanges of experience and know-how between EU and Japanese businesses. (c) Iwatani Corporation kindly allowed the use of the image on the title page in this document. Table of Contents Table of Contents ......................................................................................................................... I List of Figures ............................................................................................................................ III List of Tables ..............................................................................................................................
    [Show full text]
  • Industrial Report (C) JETRO Japan Economic Monthly, August 2005
    Industrial Report (C) JETRO Japan Economic Monthly, August 2005 Trends in the Pharmaceutical Industry Japanese Economy Division Summary The nature of Japan’s pharmaceutical market is changing. The market for generic drugs in Japan has been expanding in recent years. Major Japanese pharmaceutical companies have undertaken mergers and restructuring, and an increasing number of foreign pharmaceutical companies have entered the Japanese market recently by establishing joint ventures with Japanese drug companies or granting distribution rights for their products to Japanese firms. 1. Market Overview The Japanese pharmaceutical industry, buoyed by a rise in income levels and growing awareness about hygiene after World War II, has grown gradually in line with Japanese industry. The introduction of universal health insurance coverage in April 1961 triggered a soaring increase in domestic demand for medicines. The brisk development of new medicines based on technologies introduced from the West has enabled the industry to respond more quickly to market needs. As a result, the Japanese pharmaceutical industry is now second only to that of the United States. In recent years, however, Fig. 1-1 Japanese Market Share of Generic Drugs (GE/total drugs) the financial situation (%) Value Quantity basis surrounding health insurance has (Drug price basis) become strained due to increasing 1999 4.7 10.8 medical costs shouldered by the 20024.8 12.2 2003 5.2 16.4 government, owing to the aging Source: Japan Generic Pharmaceutical Manufacturers Association population, advances in medical Fig. 1-2 Market Shares of Generic Drugs in Main Countries technology and the development (2002) of new medical equipment.
    [Show full text]
  • 『Summary of Activities for Hydrogen Utilization in Chubu in 2030』
    1 『Summary of Activities for Hydrogen Utilization in Chubu in 2030』 February 19th, 2021 Hydrogen Utilization Study Group in Chubu ■ Eleven private companies which are promoting hydrogen utilization (listed below) have established the Hydrogen Utilization Study Group in Chubu in March 2020 to expand hydrogen demand and to build a supply chain for stable hydrogen utilization in the Chubu region. ■ This Group takes its first effort in Japan to conduct cross-sectional studies in various industries such as energy (oil, gas and electricity), petrochemicals, automobiles, steel manufacturing and finance. <Participating Companies＞ Alphabetically, ♦Secretariat companies Air Liquide Japan G.K. /Chubu Electric Power Co., Inc. /ENEOS Holdings, Inc. / Idemitsu Kosan Co., Ltd /Iwatani Corporation / Mitsubishi Chemical Corporation/ Nippon Steel Corporation /Sumitomo Corporation♦/Sumitomo Mitsui Banking Corporation♦/ Toho Gas Co., Ltd. /Toyota Motor Corporation♦ Hydrogen Utilization Study Group in Chubu 【Summary】 2 ＜Background of Study＞ On December 26, 2017, Ministry of Economy, Trade and Industry (hereinafter “METI”) published the Basic Hydrogen Strategy which included the following targets. ▽Realization of low-cost hydrogen usage under the Basic Strategy in order to move towards a hydrogen-based society: ■ As a basic approach, procurement of hydrogen at large scale, either by i) use of combination of inexpensive, unused energy of overseas markets with CCS, or ii) use of inexpensive, renewable energy to be used by electrolysis ■ Realization of annual procurement of 300 Kt/y of hydrogen, by developing commercial-scale supply chains by around 2030. Aim to realize hydrogen cost of 30 JPY/Nm3. ■ In the later phase, further endeavor to lower the hydrogen cost to 20 JPY/Nm3 to allow hydrogen to gain the same competitiveness as traditional energy sources after environmental cost adjustments are incorporated.
    [Show full text]
  • Nber Working Paper Series Did Mergers Help Japanese
    NBER WORKING PAPER SERIES DID MERGERS HELP JAPANESE MEGA-BANKS AVOID FAILURE? ANALYSIS OF THE DISTANCE TO DEFAULT OF BANKS Kimie Harada Takatoshi Ito Working Paper 14518 http://www.nber.org/papers/w14518 NATIONAL BUREAU OF ECONOMIC RESEARCH 1050 Massachusetts Avenue Cambridge, MA 02138 December 2008 The paper started as a joint project with Dr. Kelly Wang when she was Assistant Professor at University of Tokyo. The authors are grateful to her for her help in providing us with computer programs and in discussion the ways to apply her methods to the Japanese banking data. Upon Dr. Wang's departure from the University of Tokyo, the project was carried on by the current two authors with full consent from Dr. Wang. The current two authors take responsibility for any remaining errors. Mr. Shuhei Takahashi provided us with superb research assistance. We are grateful for financial support from Nomura foundation for social science and Chuo University for Special Research. We are also grateful for helpful discussions with Masaya Sakuragawa, Naohiko Baba, Satoshi Koibuchi, Woo Joong Kim, Joe Peek, Kazuo Kato and for insigutful comments from participants in Asia pacific Economic Association in Hong Kong in 2007, Japan Economic Association in 2008, NBER Japan Group Meeting in 2008 and Asian FA-NFA 2008 International Conference. The views expressed herein are those of the author(s) and do not necessarily reflect the views of the National Bureau of Economic Research. NBER working papers are circulated for discussion and comment purposes. They have not been peer- reviewed or been subject to the review by the NBER Board of Directors that accompanies official NBER publications.
    [Show full text]
  • 10/27[Thu] Press Daily Schedule
    10/27[THU] PRESS DAILY SCHEDULE TOHO Cinemas Roppongi Press Starting Ending NO. Section Title Venue Event Sign-in Guests (Tentative) Contact Info. Time Time Time Rikiya Imaizumi(Director), Koji Ichihashi(Producer), Taro Uchibori(Actor), Marika Matsumoto(Actress), Masaru TOHO CINEMAS Yahagi(Actor), Miki Akiba(Actress), Hachi Nekome(Actress), Yui TIFF Public Relations Group 1 Japanese Cinema Splash Same Old, Same Old Stage Appearance 9:30 10:20 10:35 ROPPONGI SC8 Murata(Actress), Kento Hikita(Actor), Ayaka Kawashima(Actress), +81 3 6226 3012 Mari Koike(Actress), Mao Yasuda(Actress), Chiharu Mimori(Actress), Ayano Kaneko(Theme Song) TOHO CO., LTD. TOHO CINEMAS Makoto Shinkai(Original Novel/Screenplay/Director), Yojiro Yasuhiro Toyosawa 3 Japan Now your name. Q&A 11:55 12:22 12:52 ROPPONGI SC1 Noda(RADWIMPS) +81 3 3591 3511 [email protected] TOHO CINEMAS Rikiya Imaizumi(Director), Koji Ichihashi(Producer), Taro TIFF Public Relations Group 2 Japanese Cinema Splash Same Old, Same Old Q&A 12:30 12:57 13:27 ROPPONGI SC8 Uchibori(Actor) +81 3 6226 3012 TOHO CINEMAS Jun Robles Lana(Director/Producer/Original Story), Paolo TIFF Public Relations Group 4 Competition Die Beautiful Press Conference 12:30 13:00 13:30 ROPPONGI SC6 Ballesteros(Actor), Perci Intalan(Executive Producer) +81 3 6226 3012 Sony Music Artists inc. Takeo Kikuchi(Director), Minori Hagiwara(Actress), Sayu TOHO CINEMAS Waka Uchida 5 Japanese Cinema Splash Hello, Goodbye Stage Appearance 13:45 14:35 14:50 Kubota(Actress), Masako Motai(Actress), Shunsuke ROPPONGI SC3 +81 3 5414 7351 Watanabe(Actor/ Music) [email protected] 76 Minutes and 15 Seconds TOHO CINEMAS TIFF Public Relations Group 7 World Focus with Abbas Kiarostami / Q&A 14:45 15:12 15:42 Seifollah Samadian(Director/Cinematographer/Editor/Producer) ROPPONGI SC7 +81 3 6226 3012 Take Me Home Sony Music Artists inc.
    [Show full text]
  • Press Release August 6Th, 2021 Sumitomo Corporation Chiyoda Corporation Toyota Motor Corporation Japan Research Institute, Ltd. Sumitomo Mitsui Banking Corporation
    Press Release August 6th, 2021 Sumitomo Corporation Chiyoda Corporation Toyota Motor Corporation Japan Research Institute, Ltd. Sumitomo Mitsui Banking Corporation Feasibility Study on the receiving and distribution business of imported hydrogen in Chubu Region Sumitomo Corporation (Head Office: Chiyoda-ku, Tokyo; Representative Director, President and Chief Executive Officer: Masayuki Hyodo), Chiyoda Corporation (Head Office: Yokohama City, Kanagawa Prefecture; President & COO : Masaji Santo), Toyota Motor Corporation (Head Office: Toyota City, Aichi Prefecture; President and Representative Director : Akio Toyoda), Japan Research Institute, Limited (Head Office: Shinagawa-ku, Tokyo; Representative Director, President and CEO: Katsunori Tanizaki), and Sumitomo Mitsui Banking Corporation (Head Office: Chiyoda-ku, Tokyo; President and CEO: Makoto Takashima) (collectively, “Joint Contractors”) have been appointed by the New Energy and Industrial Technology Development Organization ("NEDO") to conduct a feasibility study on the receiving and distribution business of hydrogen in Chubu Region ("Study"). NEDO selected the Joint Contractors in the public offeriing for "Development of Technologies for Realizing a Hydrogen Society/Regional Hydrogen Utilization Technology Development/Hydrogen Production and Utilization Potential Research" and the Study is scheduled to be conducted during FY2021 and FY2022. In order to promote the utilization of hydrogen in Japan, it is essential not only to produce hydrogen domestically, but also to import large volumes of hydrogen from cost competitive areas. To materialize large volume of imports, it is important to build supply chains from import terminals to demand locations, and to put priority on identifying challenges and find its solutions. Building on the previous study of potential hydrogen demand in Chubu region by the Hydrogen Utilization Study Group (“Study Group”) conducted in February 2021, this Study will focus on developing a large-scale hydrogen supply chain.
    [Show full text]
  • Introduction
    Hypertension Research (2014) 37, 256–259 & 2014 The Japanese Society of Hypertension All rights reserved 0916-9636/14 www.nature.com/hr GUIDELINES (JSH 2014) Introduction Hypertension Research (2014) 37, 256–259; doi:10.1038/hr.2014.18 The Japanese Society of Hypertension revised the Japanese Society of JSH 2014 should also be used by health nurses, nurses, dietitians and Hypertension Guidelines for the Management of Hypertension in staff responsible for team practice for hypertension management. 2009 (JSH 2009) and published the JSH 2014. Basically, the JSH 2014 Therefore, in addition to specialists in hypertension, the members of was prepared according to strategies to prepare the JSH 2009 and the The Japan Association of Medical Practitioners, The Japanese Society ‘Guidance for the Preparation of Treatment Guidelines in 2007’ of Clinical Pharmacology and Therapeutics, Japan Pharmaceutical established by the Medical Information Network Distribution Service. Association, Japanese Society of Clinical Nutrition, and Patient In the ‘Introduction’ section, methods to prepare the JSH 2014 are Corporation belong to the Japanese Society of Hypertension Com- introduced. mittee for Guidelines for the Management of Hypertension. With regard to the affiliations of the committee members, their occupation, 1. OBJECTIVE AND SUBJECTS OF THE JSH 2014 affiliated corporations and positions are described. Hypertension causes stroke (cerebral infarction, cerebral hemorrhage, subarachnoidal hemorrhage), heart disease (coronary artery disease, 2. COMPOSITION OF THE JAPANESE SOCIETY OF cardiac hypertrophy, heart failure), kidney disease (nephrosclerosis) HYPERTENSION COMMITTEE FOR GUIDELINES FOR THE and macrovascular disease. Therefore, the primary objective MANAGEMENT OF HYPERTENSION of the JSH 2014 is to present standard treatment to prevent the The Japanese Society of Hypertension Guidelines for the Management onset/progression of hypertensive complications of the brain/heart/ of Hypertension is official.
    [Show full text]
  • Toho Gas Group Initiatives[PDF:3.39MB]
    Grow with Energy̶Go beyond Energy Toho Gas Group Initiatives Strategy 3 Taking on New Scopes Strategy 2 Enhance energy-related businesses Development into at home and abroad and Strategy 1 a Total Energy Provider venture into new business scopes Toho Gas Group Initiatives FY2019‒FY2021 that bring synergy effects. Further Growth of Offer optimal proposals for the City Gas Business the three different energies and provide added value through Toho Gas Group Ensure safety, security and stable supply. new services. Further strengthen cost competitiveness. Medium-Term Management Plan Deepen relationship with customers. Grow with Energy ̶ Go beyond Energy In November 2018, the Toho Gas Group formulated a new Medium-term Management Plan (FY2019 Reinforcing the business foundation of the Toho Gas Group ‒FY2021). By implementing our three key strategies while reinforcing our business foundation, we will In addition to ensuring the stable operation of the energy business, reinforce our business foundation to flexibly respond to changes in the business environment, aiming to achieve sustainable growth. further strengthen our position as an energy company that is trusted by customers and has strong roots in Reinforcement and Use of Human Resources / Improvement of Efficiency / Reform of the Organizational local communities. We will also further expand our business scope to achieve sustainable growth. Structure / Technological Development for the Future / Promotion of ESG Management Strategy 1 Strategy 2 Strategy 3 Further Growth of Development into
    [Show full text]
  • Pxlymseries Pxlymseries
    %XOE&LUFXLW 5HOD\Interface Unit PXLYMseries PXLYMseries Standard bulb circuit and protection in one unit, allowing users to integrate a system only wiring bulbs to the unit. Features ● Select from 16 and 32 I/O points. ● Select from different fuses depending on purpose. ● Connect to both NPN and PNP devices. ●PNP for input and output ●NPN for output P P Load …Connected to P side Load …Connected to N side N N ●DRY回路 ● DRY Wet contact outputs接点出力 do notP N ●WET circuit require externalRY interface 負荷 terminals. WET contact output RY RY Load 負荷 RY Load 外部で電源渡りが必要 N P One side of contacts are connected 1 ● Switches allow users to control ON/OFF directly, making it ideal for debugging, trial, testing, and maintenance of equipment. Switch P PLC AUTO RY OFF ON AUTO ：PLCFRQWUROHG OFF ：$OZD\VOFF N ON ：)RUFHG21 +ROGWRJJOHVZLWFKLQVWDOOHG ● Alarm signal indicator in case of fuse リレー交換による仕様変更 blowout. Xn F 2XWSXW Alarm Fuse blowout indication ●PDQXIDFWXUHUVRIUHOD\VDUHDYDLODEOH 《2PURQ／3DQDVRQLF／)XML(OHFWULF／,'(&／7\FR$03》 ●W\SHVRIWHUPLQDOEORFNVDUHDYDLODEOH 6WDQGDUGTHUPLQDO 6SULQJLLIWHGTHUPLQDO 5HPRYDEOHSSULQJLLIWHGTHUPLQDO 2 PXLYMseries ●特●特 長 ●外形寸法図●外形寸法図 ●回路図●回路図 ●各部寸法／価格●各部寸法／価格 ●搭載コネクー一覧●搭載コネクタ一覧 ●+RZTROUGHU ●使用コネクタ一覧●使用コネクタ一覧 ●一般仕様●一般仕様 ●対応●対応PLC入出力ユニット一覧 PX LY M16 6F­D02 OP ­HP1A ­CM F2 ●海外規格仕様●海外規格仕様 ­●リレー・●Vリレー・SSR組合せ表 Relay I/O Qty. I/O Type Coating Specification I­W : for input ●使用例●MY使用例 ：MY2 ( Omron ) 8 ●搭載ヒューズ定格電流一覧:● 8 points搭載ヒューズ定格電流一覧 LY ：LY2（ Omron ) 16 :16 points I­CW ：for input Blank : Paint once HJ ：HJ2（ Panasonic ) OP ：PNP output
    [Show full text]
  • Ural Gas Strategy of Toho Gas Group
    Excellent Characteristics of Natural Gas Strategy of Toho Gas Group Natural gas, which is the main product of Toho Gas, is supplied stably. Expansion of its use is expected in the Toho Gas developed a medium-term management plan In order to build a robust gas business, we will enhance environment-friendly. It exists abundantly and can be future. (FY2014 to FY2018) in March 2014. The concepts of this the Group’s comprehensive business capability through plan are“Build a robust gas business” and“Realize further “ensuring stable energy supply, safety and security,” growth.” In April 2017, the gas market was fully liberalized, “strengthening our relationship with customers” and Environment Friendly following the complete liberalization of the electricity “strengthening competitiveness.” Accordingly, we will work market in April 2016, and the business environment toward achieving a liberalization of the gas market which is Natural gas, which is primarily composed of methane, Emissions of combustion by-products from fossil fuels surrounding our company has been changing dramatically. truly beneficial to customers, and aim to become a compa- when burned, generates only small amounts of carbon (Coal = 100) By precisely and flexibly responding to the changes in the ny that continues to be trusted and chosen by customers. In dioxide that is the key contributors to global warming and business environment, the Toho Gas Group will strive to order Toho Gas Group achieve further growth, we will Natural gas Natural gas nitrogen oxide that causes photochemical smog, and sulfur Natural gas 20～37 57 0 attain sustainable growth while aiming to achieve the two expand our gas business service area and scope of business.
    [Show full text]
  • Toho Water Authority 101 North Church Street, 2" D Floor HEAR
    Toho Water Authority 101 North Church Street, 2" d Floor Kissimmee, FL 34741 www. tohowater. com rt.; Board of Supervisors Q tZ Bruce R. Van Meter, Chairman Brian L. Wheeler, Executive Director Mary Jane Arrington, Vice Chairman Mike Davis, Attorney John E. Moody, Supervisor Steve Johnson, Attorney John C. Reich, Supervisor James W. Wells, Supervisor AGENDA JUNE 13, 2007 5: 00 PM 1. 18 1: 9: 0910[ eTiy_l41: 19-jfoxelV7: I 7 2. 110 • • Z = 111111 ' l _ • _ ; 3. 4. 5. I1p] 1.1a[ rlaNr_1GZ10 6. HEAR AUDIENCE ( Anything requiring a vote will be heard at a later date) 7. CONSENT AGENDA The Consent Agenda is a technique designed to expedite handling of routine and miscellaneous business of the Board of Supervisors. The Board of Supervisors in one motion may adopt the entire Agenda. The motion for adoption is non - debatable and must receive unanimous approval. By request of any individual member, any item may be removed from the Consent Agenda and placed upon the Regular Agenda for debate. A. APPROVAL OF DEVELOPER SERVICE AGREEMENT AMENDMENT FOR BOCA PALMS B. APPROVAL OF MODIFICATION OF THE POINCIANA BLVD PHASE 1 RESIDENT PROJECT REPRESENTATIVE SERVICES SCOPE OF SERVICES TO ALLOW RESIDENT PROJECT REPRESENTATIVE SERVICES ON OTHER PROJECTS CURRENTLY UNDER CONSTRUCTION C. APPROVAL OF CONSTRUCTION CONTRACT WITH GIBBS & REGISTER, INC. FOR IMPROVEMENTS TO LIFT STATION # 6 AND LIFT STATION # 116 D. APPROVAL SURPLUS PORPERTY AUCTION AND ASSET DISPOSAL LIST 8. INFORMATIONAL PRESENTATIONS ( REQUIRING NO ACTION) LANGHAM CONSULTING SERVICES, INC. 9. OLD BUSINESS: A. APPROVAL OF PILOT PROGRAM FOR WATER CONSERVATION STAFFING B.
    [Show full text]